Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.): Caspofungin Acetate Injection to be discontinued
Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.): Caspofungin Acetate Injection to be discontinued. Its amount of 2 is below the median of 3 (48th percentile). Dated 128 days ago, it serves as a historical benchmark. Score 60/100. As of 2026-11-05, from openFDA drug shortages endpoint (U.S. Food and Drug Administration drug shortage list).
Data as of · Compiled by Zalwin from openFDA drug shortages endpoint (U.S. Food and Drug Administration drug shortage list)
amount: 2 · 48th percentile of 358 DrugShortagePulse records · 0.7x the median
Free preview: all 12 published fields of this record are shown below. Locked: 357 related DrugShortagePulse records and the 5-column CSV export.
| Field | Value |
|---|---|
| Manufacturer | Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) |
| Drug | Caspofungin Acetate Injection |
| Dosage form | Injection |
| Therapeutic category | Anti-Infective |
| Status | To Be Discontinued |
| Stage | Manufacturer discontinuation |
| Presentations affected | 2 |
| Package NDCs | 0781-3421-94, 0781-3423-94 |
| Manufacturer supply note | Marketed by Sandoz, Inc.; Discontinuation of the manufacture of the drug |
| Discontinued date | 2026-06-30 |
| First posted | 2026-06-30 |
| Updated | 2026-06-30 |
| amount percentile | 48th of 358 (median 3, 0.7x median) |
| Peer records CSV (358 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) + all 358 records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Manufacturer · Drug · Stage · Availability · Updated · official source URL
- Source agency: openFDA drug shortages endpoint (U.S. Food and Drug Administration drug shortage list)
- Record date: 2026-06-30
- Data refreshed: 2026-11-05
- Refunds on request within 14 days
Top DrugShortagePulse records: Sanofi-Aventis U.S. LLC · Fresenius Kabi USA, LLC · Fresenius Kabi USA, LLC · Hospira, Inc., a Pfizer Company · Hospira, Inc., a Pfizer Company · Browse all by state and category →
LIVE PUBLIC DATA Source: openFDA drug shortages endpoint (U.S. Food and Drug Administration drug shortage list) · Last refreshed: Thu, 05 Nov 2026 09:00:14 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
60 / 100 Score
- The manufacturer is leaving the market.
- Sterile injectable: hospital and 503B demand.
What is the DrugShortagePulse record for Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)?
Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)'s Caspofungin Acetate Injection is on the FDA drug shortage list. Manufacturer discontinuation. Last updated 2026-06-30.
How does Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) compare to other DrugShortagePulse records?
Its amount of 2 is below the median (48th percentile); smaller records often move faster and face less competition. It is 128 days old; check the official source for later updates before acting.
Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) vs. top 3 peers
| Organization | Amount | Percentile | Record date | Compare |
|---|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) | 2 | 48th | 2026-06-30 | This record |
| Baxter Healthcare | 2 | 48th | 2026-10-30 | Compare Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) vs Baxter Healthcare → |
| Baxter Healthcare | 2 | 48th | 2026-10-30 | Compare Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) vs Baxter Healthcare → |
| Par Health, USA LLC | 2 | 48th | 2026-09-11 | View record → |
Related records
- Baxter Healthcare
- Baxter Healthcare
- Baxter Healthcare
- Sanofi-Aventis U.S. LLC
- Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)
- Fresenius Kabi USA, LLC
- Fresenius Kabi USA, LLC
- Par Health, USA LLC
- Hospira, Inc., a Pfizer Company
- Merck Sharp & Dohme LLC
- Eli Lilly and Co.
- Eli Lilly and Co.
DrugShortagePulse: Manufacturer discontinuation DrugShortagePulse: Anti-Infective
How to monitor Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) and peer anti-infective records
Get new DrugShortagePulse records like Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new shortages in your categories
DrugShortagePulse emails new and changed FDA drug shortages matching your therapeutic categories.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From the openFDA drug shortages endpoint, which mirrors the FDA drug shortage list and can lag it by days. Availability and recovery notes are the manufacturer's own statements to FDA. Company and product level only. Verify with FDA and the manufacturer before acting.